Bullish OTC microcap ADHC on GlucoGuard diabetes device, pending FDA Breakthrough designation, DXCM partnership, and a third-party CFA valuation far above current market cap.
Unpriced research observations (excluded from Calls and Returns):
ADHC — LONG The author argues ADHC is an unusually rare OTC opportunity because its ~$1M market cap is extremely low for a diabetes medical device company, with the discount attributed to OTC listing, low visibility and low volume versus Nasdaq peers. Catalysts cited include a pending FDA Breakthrough Device designation for GlucoGuard, a partnership with DXCM, hedge fund backing, and a Harbinger Research CFA report dated June 2, 2025 rating it Strong Speculative Buy with a $0.012 price target ($43M valuation). The author notes the stock recently found support in the .0005 range and had big run-ups in the past, framing it as a radar/watch candidate from these levels. resolved_entity_name_mismatch
What makes this one even more interesting is the current market cap of $1M which is extremely low for a diabetes medical device company. In a CFA research report the company was given a $43M valuation.